Abstract
Etanercept-induced organizing pneumonia (OP) has not been reported in Japan. We describe the case of a rheumatoid arthritis patient who developed OP during etanercept treatment and discuss the possible mechanisms underlying the development of etanercept-induced OP and the existence of factors that predispose Japanese patients to drug-induced OP.
MeSH terms
-
Antirheumatic Agents / adverse effects*
-
Arthritis, Rheumatoid / complications
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / pathology
-
Cryptogenic Organizing Pneumonia / chemically induced*
-
Cryptogenic Organizing Pneumonia / drug therapy
-
Cryptogenic Organizing Pneumonia / pathology
-
Cysteine / analogs & derivatives
-
Cysteine / therapeutic use
-
Drug Therapy, Combination
-
Etanercept
-
Female
-
Humans
-
Immunoglobulin G / adverse effects*
-
Methotrexate / therapeutic use
-
Middle Aged
-
Radiography, Thoracic
-
Receptors, Tumor Necrosis Factor
-
Treatment Outcome
Substances
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Cysteine
-
Etanercept
-
bucillamine
-
Methotrexate